Venus Medtech (Hangzhou), Inc. Class H
OTC: VMTHF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Hou-Sen Lim
- Employees
- 563
- Headquarters
- Wanchai, China
- IPO year
- 2021
- Market cap
- $186.1M
- Website
- https://www.venusmedtech.com
Loading VMTHF…
Loading profile data…Frequently asked questions about VMTHF
What does Venus Medtech (Hangzhou), Inc. Class H (VMTHF) do?
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-...
Where does VMTHF trade?
Venus Medtech (Hangzhou), Inc. Class H (VMTHF) trades on the Other OTC.
What sector is VMTHF in?
Venus Medtech (Hangzhou), Inc. Class H (VMTHF) operates in the Healthcare sector, specifically in the Medical - Specialties industry.
Who is the CEO of Venus Medtech (Hangzhou), Inc. Class H?
Hou-Sen Lim is the chief executive officer of Venus Medtech (Hangzhou), Inc. Class H (VMTHF).
Where is Venus Medtech (Hangzhou), Inc. Class H headquartered?
Venus Medtech (Hangzhou), Inc. Class H is headquartered in China.
Does VMTHF pay a dividend?
Venus Medtech (Hangzhou), Inc. Class H (VMTHF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VMTHF go public?
Venus Medtech (Hangzhou), Inc. Class H (VMTHF) completed its initial public offering in 2021.